From our founding, we made the decision that we’d be different

In the way we’re structured, in the people we hire, in our trials and technology—and in the way we research and innovate the transformative solutions on the frontiers of oncology, autoimmune disease, and pain management.

Shifting toward disease-centric therapies, we seek to treat patients holistically, allowing us to target diseases and their consequences on the human body on multiple levels.

Shifting our approach to treating cancer
Research

Shifting our approach to treating cancer

The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1

Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform, our immuno-oncology assets currently in Phase 1 clinical trials facilitate binding of powerful immune cells called CD3 (or T cells) to HER2 and CD38 expressing tumors.2 This may allow for the treatment of cancers such as breast and multiple myeloma, including those non-responsive or resistant to standard of care.

We believe our path to innovation holds great promise for the future, to treat cancer differently.


Research

The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1

Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform, our immuno-oncology assets currently in Phase 1 clinical trials facilitate binding of powerful immune cells called CD3 (or T cells) to HER2 and CD38 expressing tumors.2 This may allow for the treatment of cancers such as breast and multiple myeloma, including those non-responsive or resistant to standard of care.

We believe our path to innovation holds great promise for the future, to treat cancer differently.

Shifting novel autoimmune disease treatments forward
research

Shifting novel autoimmune disease treatments forward

At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.

With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX-40.3 By blocking OX-40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3

Currently in Phase 2b clinical trials for atopic dermatitis, ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions.4 The treatment may change lives, and the way autoimmune disease are treated—from now on.


research

At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.

With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX-40.3 By blocking OX-40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3

Currently in Phase 2b clinical trials for atopic dermatitis, ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions.4 The treatment may change lives, and the way autoimmune disease are treated—from now on.

Shifting from pain to progress
research

Shifting from pain to progress

For too long, pain management as a clinical area of focus has cried out for change.5 We’re committed to bringing responsible pain management medication forward.

Our goal is to develop differentiated medicines that will help individuals suffering from pain return to a better quality of life. We believe our holistic focus on diseases and patients will get us there faster.

Because the world is waiting.


research

For too long, pain management as a clinical area of focus has cried out for change.5 We’re committed to bringing responsible pain management medication forward.

Our goal is to develop differentiated medicines that will help individuals suffering from pain return to a better quality of life. We believe our holistic focus on diseases and patients will get us there faster.

Because the world is waiting.

Science shifted

We’re changing medicine. Here’s how.

Current Pipeline of Clinical Stage Assets

Molecule*
Potential Indication(s)
Mechanism / CLASS
Pre-CLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVAL

ONCOLOGY

ISB 1302
HER2 positive cancers such as breast cancer
HER2xCD3
(BEAT® bsAb)
40%
ISB 1342
Multiple myeloma
CD38xCD3
(BEAT® bsAb)
30%

Autoimmune Disease

ISB 830
Atopic dermatitis
OX40 Antagonist (mAb)
55%

Pain

ISC 17536
Neuropathic pain
TRPA 1 antagonist
45%

ONCOLOGY

Molecule*
ISB 1302
Potential Indication(s)
HER2 positive cancers such as breast cancer
Mechanism / CLASS
HER2xCD3
(BEAT® bsAb)
Status
PHASE 2
Molecule*
ISB 1342
Potential Indication(s)
Multiple myeloma
Mechanism / CLASS
CD38xCD3
(BEAT® bsAb)
Status
PHASE 1

Autoimmune Disease

Molecule*
ISB 830
Potential Indication(s)
Atopic dermatitis
Mechanism / CLASS
OX40 Antagonist (mAb)
Status
PHASE 2

Pain

Molecule*
ISC 17536
Potential Indication(s)
Neuropathic pain
Mechanism / CLASS
TRPA 1 antagonist
Status
PHASE 2

1.

Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Seminars in Cancer Biology 52, 39–52 (2018).

2.

Glenmark Pharmaceuticals S.A. Glenmark Bispecific Clinical Trials. Available here. NLM identifiers: NCT03983395, NCT02829372, NCT03309111. Accessed: 12th August 2019.

3.

Guttman-Yassky, E. et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J. Allergy Clin. Immunol. 144, 482-493.e7 (2019).

4.

Glenmark Pharmaceuticals S.A. GBR 830 Clinical Trials. Available here. NLM identifiers: NCT02683928, NCT03568162. (Accessed: 12th August 2019).

5.

Pergolizzi, J. V, Paladini, A., Varrassi, G. & Raffa, R. B. Change Pain: Ever Evolving—An Update for 2016. Pain Ther. 5, 127–133 (2016).

* Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.

View Career Opportunities

United States

Switzerland

India

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue

You are now leaving the Ichnos Sciences Inc. website.


The link you have selected is provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.


Cancel Continue